The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by RFA-HL-23-012.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 6
- 6 new
- Median first-year cost
- $563,131
- $3,312,017 in all
- Institutions
- 6
- 6 contact PIs
Awards by fiscal year
0
0
0
0
0
0
3
1
2
0
0
0
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- BOSTON CHILDREN'S HOSPITAL1
- MASSACHUSETTS GENERAL HOSPITAL1
- MICROVASCULAR THERAPEUTICS, LLC1
- OHIO STATE UNIVERSITY1
- TEXAS HEART INSTITUTE1
and 1 other institution
Most frequent study sections
- Special Emphasis Panel (ZHL1 CSR-R (M1))3
- Special Emphasis Panel (ZHL1 CSR-F (O1))2
- Special Emphasis Panel (ZHL1 CSR-R (O1))1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2022 | Developing a Novel E3 Ligase based Anti-inflammatory for ARDS1R33HL157877-01A1 | Mallampalli, Rama K | OHIO STATE UNIVERSITY, OH | First-year cost $551,250 | Study section ZHL1 |
| FY2022 | Optimization of small molecule integrin activators to enhance cord blood transplant1R33HL161778-01 | Biediger, Ronald JVanderslice, Peter | TEXAS HEART INSTITUTE, TX | First-year cost $547,028 | Study section ZHL1 |
| FY2021 | Ultrasound-mediated thrombolysis for MVO and PAO treatment.1R33HL156350-01 | Meuillet, Emmanuelle JoellePacella, John J | MICROVASCULAR THERAPEUTICS, LLC, AZ | First-year cost $575,012 | Study section ZHL1 |
| FY2020 | Novel small molecules to treat degenerative lung and blood diseases1R33HL154133-01 | Agarwal, Suneet | BOSTON CHILDREN'S HOSPITAL, MA | First-year cost $619,500 | Study section ZHL1 |
| FY2020 | Optimization of PET probe for imaging lung fibrogenesis1R33HL154125-01 | Caravan, Peter D | MASSACHUSETTS GENERAL HOSPITAL, MA | First-year cost $588,000 | Study section ZHL1 |
| FY2020 | Preclinical Development of a Novel Disease Modifying Therapy for Pulmonary Arterial Hypertension1R33HL154135-01 | Singh, Jaipal | VASCULONICS, LLC, IN | First-year cost $431,227 | Study section ZHL1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-14-0.3.3. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.